{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:16:23Z","timestamp":1784556983337,"version":"3.55.0"},"reference-count":66,"publisher":"Bioscientifica","issue":"6","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ec.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:p>The aim of this study was to evaluate the clinical usefulness of the chromogranin A (CgA) determination in patients with neuroendocrine neoplasms (NENs) of the digestive system and to analyse the association between concentration of the marker and progression-free survival (PFS) and overall survival (OS). Serum concentrations of CgA were determined before the treatment in 131 patients with NENs, including patients with tumours located in the pancreas, the small intestine, caecum, appendix and in the colon. No significant associations were identified in CgA concentrations between the control group and patients with NENs in appendix and colon. In patients with NENs of the pancreas and NENs of the small intestine and caecum, increased CgA levels were associated with lymph node involvement, distant metastases and a baseline liver involvement. Analyses revealed significantly higher CgA concentrations in patients with active disease compared to those without symptoms of NEN. In patients with NENs of the pancreas, CgA concentration was correlated with tumour grade and Ki67. Significantly higher CgA levels were also found in patients who died compared to those who lived. Analyses of PFS and OS revealed that CgA concentration was not a prognostic factor in patients with NENs of the pancreas. In patients with NENs of the small intestine and caecum, increased CgA concentrations are independent, poor prognostic factors for both PFS and OS. In conclusion, in patients with NENs in pancreas, CgA levels are associated with disease progression, while in patients with NENs in small intestine and caecum, its concentration is a predictive indicator for PFS and OS.<\/jats:p>","DOI":"10.1530\/ec-18-0059","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T12:01:04Z","timestamp":1525348864000},"page":"803-810","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic value of chromogranin A in patients with GET\/NEN in the pancreas and the small intestine"],"prefix":"10.1530","volume":"7","author":[{"given":"Ma\u0142gorzata","family":"Fuksiewicz","sequence":"first","affiliation":[{"name":"1Department of Pathology and Laboratory Diagnostics, Laboratory of Tumor Markers, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Kowalska","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Diagnostics, Laboratory of Tumor Markers, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnieszka","family":"Kolasi\u0144ska-\u0106wik\u0142a","sequence":"additional","affiliation":[{"name":"2Department of Oncology and Radiotherapy, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw B","family":"\u0106wik\u0142a","sequence":"additional","affiliation":[{"name":"3The Faculty of Medical Sciences, University of Warmia and Mazury, Olsztyn, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Sawicki","sequence":"additional","affiliation":[{"name":"4Department of Clinical Surgery, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Roszkowska-Purska","sequence":"additional","affiliation":[{"name":"5Department of Pathology, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Drygiel","sequence":"additional","affiliation":[{"name":"6Department of Nutrition, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beata","family":"Kotowicz","sequence":"additional","affiliation":[{"name":"1Department of Pathology and Laboratory Diagnostics, Laboratory of Tumor Markers, Maria Sklodowska-Curie Institute \u2013 Oncology Center, Warsaw, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"ref531","first-page":"184","article-title":"Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina","volume":"39","year":"2009","journal-title":"Acta Gastroenterologica Latinoamericana"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"72716","DOI":"10.18632\/oncotarget.12237","article-title":"Regulation of tumor growth by circulating full-length chromogranin A","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"ref341","first-page":"79","article-title":"Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)","volume":"68","year":"2017","journal-title":"Polish Endokrynology"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/his.12766","article-title":"Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome","volume":"68","year":"2016","journal-title":"Histopathology"},{"key":"ref551","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1472-6823-14-64","article-title":"Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas","volume":"14","year":"2014","journal-title":"BMC Endocrine Disorders"},{"key":"ref561","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.surg.2017.01.019","article-title":"Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: a prospective observational study from a single institute","volume":"162","year":"2017","journal-title":"Surgery"},{"key":"ref461","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.plabm.2015.03.002","article-title":"Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system","volume":"1","year":"2015","journal-title":"Practical Laboratory Medicine"},{"key":"ref31","first-page":"215","article-title":"Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors","volume":"3","year":"2014","journal-title":"Gland Surgery"},{"key":"ref231","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.surg.2017.01.019","article-title":"Diagnostic value of chromogranin A in pancreatic neuroendocrine tumors depends on tumor size: a prospective observational study from a single institute","volume":"162","year":"2017","journal-title":"Surgery"},{"key":"ref221","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/1472-6823-14-64","article-title":"Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas","volume":"14","year":"2014","journal-title":"BMC Endocrine Disorders"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12031-012-9728-2","article-title":"Chromogranin A and derived peptides in health and disease","volume":"48","year":"2012","journal-title":"Journal of Molecular Neuroscience"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000472254","article-title":"Antibes Consensus Conference participants. ENETS Consensus Guidelines for standard of care in neuroendocrine tumours: biochemical markers","volume":"105","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref01","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","year":"2010","journal-title":"Pancreas"},{"key":"ref581","doi-asserted-by":"crossref","first-page":"596","DOI":"10.4143\/crt.2015.029","article-title":"Appendiceal neuroendocrine, goblet and signet-ring cell tumors: a spectrum of diseases with different patterns of presentation and outcome","volume":"48","year":"2016","journal-title":"Cancer Research and Treatment"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pan.2016.12.012","article-title":"Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: a potential predictor of postoperative recurrence","volume":"17","year":"2017","journal-title":"Pancreatology"},{"key":"ref591","first-page":"27","article-title":"Appendiceal neuroendocrine neoplasms: diagnosis and management","volume":"23","year":"2016","journal-title":"Endocrine-Related Cancer"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.plabm.2015.03.002","article-title":"Evaluation of a new immunoassay for chromogranin A measurement on the Kryptor system","volume":"1","year":"2015","journal-title":"Practical Laboratory Medicine"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1245\/s10434-014-3728-0","article-title":"Pancreastatin predicts survival in neuroendocrine tumors","volume":"21","year":"2014","journal-title":"Annals of Surgical Oncology"},{"key":"ref201","first-page":"184","article-title":"Chromogranin A as a biochemical marker for the management of neuroendocrine tumors: a multicenter study developed in Argentina","volume":"39","year":"2009","journal-title":"Acta Gastroenterologica Latinoamericana"},{"key":"ref281","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-12-0340","article-title":"Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database","volume":"20","year":"2013","journal-title":"Endocrine-Related Cancer"},{"key":"ref621","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1245\/s10434-014-3728-0","article-title":"Pancreastatin predicts survival in neuroendocrine tumors","volume":"21","year":"2014","journal-title":"Annals of Surgical Oncology"},{"key":"ref641","first-page":"227","article-title":"The value of serum chromogranin A as predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases","volume":"27","year":"2015","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"ref361","first-page":"215","article-title":"Biochemical prognostic indicators for pancreatic neuroendocrine tumors and small bowel neuroendocrine tumors","volume":"3","year":"2014","journal-title":"Gland Surgery"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2016-0455","article-title":"Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors","volume":"13","year":"2017","journal-title":"Future Oncology"},{"key":"ref501","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/his.12766","article-title":"Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome","volume":"68","year":"2016","journal-title":"Histopathology"},{"key":"ref631","doi-asserted-by":"crossref","first-page":"e0124884","DOI":"10.1371\/journal.pone.0124884","article-title":"Diagnostic value of circulating chromogranin A for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"ref601","doi-asserted-by":"crossref","first-page":"e0154679","DOI":"10.1371\/journal.pone.0154679","article-title":"Circulating chromogranin A as a marker for monitoring clinical response in advanced gastroenteropancreatic neuroendocrine tumors","volume":"11","year":"2016","journal-title":"PLoS ONE"},{"key":"ref421","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00018-014-1750-9","article-title":"Chromogranin A: a paradoxical player in angiogenesis and vascular biology","volume":"72","year":"2015","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"419","DOI":"10.15403\/jgld.2014.1121.234.3ca","article-title":"A comparison of three chromogranin A assays in patients with neuroendocrine tumours","volume":"23","year":"2014","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"ref541","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/cas.12533","article-title":"Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors","volume":"105","year":"2014","journal-title":"Cancer Sciences"},{"key":"ref331","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/MPA.0b013e3181ec124e","article-title":"The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems","volume":"39","year":"2010","journal-title":"Pancreas"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"596","DOI":"10.4143\/crt.2015.029","article-title":"Appendiceal neuroendocrine, goblet and signet-ring cell tumors: a spectrum of diseases with different patterns of presentation and outcome","volume":"48","year":"2016","journal-title":"Cancer Research and Treatment"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1111\/cas.12533","article-title":"Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors","volume":"105","year":"2014","journal-title":"Cancer Sciences"},{"key":"ref351","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000472254","article-title":"Antibes Consensus Conference participants. ENETS Consensus Guidelines for standard of care in neuroendocrine tumours: biochemical markers","volume":"105","year":"2017","journal-title":"Neuroendocrinology"},{"key":"ref271","doi-asserted-by":"crossref","first-page":"e0154679","DOI":"10.1371\/journal.pone.0154679","article-title":"Circulating chromogranin A as a marker for monitoring clinical response in advanced gastroenteropancreatic neuroendocrine tumors","volume":"11","year":"2016","journal-title":"PLoS ONE"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease","volume":"17","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s13277-015-4114-7","article-title":"Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors","volume":"37","year":"2016","journal-title":"Tumor Biology"},{"key":"ref381","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000369818","article-title":"Chromogranin A in diagnosing and monitoring patients with gastro-entero-pancreatic neuroendocrine neoplasms. A large series from a single institution","volume":"100","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.2217\/fon-2016-0455","article-title":"Baseline chromogranin A and its dynamics are prognostic markers in gastroenteropancreatic neuroendocrine tumors","volume":"13","year":"2017","journal-title":"Future Oncology"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"419","DOI":"10.15403\/jgld.2014.1121.234.3ca","article-title":"A comparison of three chromogranin A assays in patients with neuroendocrine tumours","volume":"23","year":"2014","journal-title":"Journal of Gastrointestinal and Liver Diseases"},{"key":"ref411","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2012-05-430314","article-title":"A new chromogranin A-dependent angiogenic switch activated by thrombin","volume":"121","year":"2013","journal-title":"Blood"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1159\/000369818","article-title":"Chromogranin A in diagnosing and monitoring patients with gastro-entero-pancreatic neuroendocrine neoplasms. A large series from a single institution","volume":"100","year":"2014","journal-title":"Neuroendocrinology"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.regpep.2010.02.011","article-title":"Granins and granin-related peptides in neuroendocrine tumours","volume":"165","year":"2010","journal-title":"Regulatory Peptides"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"72716","DOI":"10.18632\/oncotarget.12237","article-title":"Regulation of tumor growth by circulating full-length chromogranin A","volume":"7","year":"2016","journal-title":"Oncotarget"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00424-017-2030-y","article-title":"Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers","volume":"470","year":"2018","journal-title":"Pflu\u0308gers Archiv: European Journal of Physiology"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1097\/MD.0000000000000247","article-title":"Chromogranin a as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm","volume":"93","year":"2014","journal-title":"Medicine"},{"key":"ref471","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s12031-012-9728-2","article-title":"Chromogranin A and derived peptides in health and disease","volume":"48","year":"2012","journal-title":"Journal of Molecular Neuroscience"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1245\/s10434-010-1006-3","article-title":"Chromogranin A-biological function and clinical utility in neuroendocrine tumor disease","volume":"17","year":"2010","journal-title":"Annals of Surgical Oncology"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13493","article-title":"Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy","volume":"119","year":"2017","journal-title":"BJU International"},{"key":"ref301","doi-asserted-by":"crossref","first-page":"e0124884","DOI":"10.1371\/journal.pone.0124884","article-title":"Diagnostic value of circulating chromogranin A for neuroendocrine tumors: a systematic review and meta-analysis","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"ref261","first-page":"27","article-title":"Appendiceal neuroendocrine neoplasms: diagnosis and management","volume":"23","year":"2016","journal-title":"Endocrine-Related Cancer"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1182\/blood-2012-05-430314","article-title":"A new chromogranin A-dependent angiogenic switch activated by thrombin","volume":"121","year":"2013","journal-title":"Blood"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.pan.2016.12.012","article-title":"Baseline plasma chromogranin A levels in patients with well-differentiated neuroendocrine tumors of the pancreas: a potential predictor of postoperative recurrence","volume":"17","year":"2017","journal-title":"Pancreatology"},{"key":"ref311","first-page":"227","article-title":"The value of serum chromogranin A as predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases","volume":"27","year":"2015","journal-title":"European Journal of Gastroenterology and Hepatology"},{"key":"ref511","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bju.13493","article-title":"Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy","volume":"119","year":"2017","journal-title":"BJU International"},{"key":"ref651","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1007\/s13277-015-4114-7","article-title":"Serum chromogranin A levels for the diagnosis and follow-up of well-differentiated non-functioning neuroendocrine tumors","volume":"37","year":"2016","journal-title":"Tumor Biology"},{"key":"ref611","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1530\/ERC-12-0340","article-title":"Clinical presentation, recurrence, and survival in patients with neuroendocrine tumors: results from a prospective institutional database","volume":"20","year":"2013","journal-title":"Endocrine-Related Cancer"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/egh.12.15","article-title":"Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors","volume":"6","year":"2012","journal-title":"Expert Review of Gastroenterology and Hepatology"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1586\/egh.12.15","article-title":"Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors","volume":"6","year":"2012","journal-title":"Expert Review of Gastroenterology and Hepatology"},{"key":"ref521","doi-asserted-by":"crossref","first-page":"e247","DOI":"10.1097\/MD.0000000000000247","article-title":"Chromogranin a as a marker for diagnosis, treatment, and survival in patients with gastroenteropancreatic neuroendocrine neoplasm","volume":"93","year":"2014","journal-title":"Medicine"},{"key":"ref11","first-page":"79","article-title":"Diagnostic and therapeutic guidelines for gastro-entero-pancreatic neuroendocrine neoplasms (recommended by the Polish Network of Neuroendocrine Tumours)","volume":"68","year":"2017","journal-title":"Polish Endokrynology"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00018-014-1750-9","article-title":"Chromogranin A: a paradoxical player in angiogenesis and vascular biology","volume":"72","year":"2015","journal-title":"Cellular and Molecular Life Sciences"},{"key":"ref441","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00424-017-2030-y","article-title":"Circulating chromogranin A and its fragments as diagnostic and prognostic disease markers","volume":"470","year":"2018","journal-title":"Pflu\u0308gers Archiv: European Journal of Physiology"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.2174\/092986712802429975","article-title":"Chromogranin A and the endothelial barrier function","volume":"19","year":"2012","journal-title":"Current Medicinal Chemistry"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.2174\/092986712802429975","article-title":"Chromogranin A and the endothelial barrier function","volume":"19","year":"2012","journal-title":"Current Medicinal Chemistry"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.regpep.2010.02.011","article-title":"Granins and granin-related peptides in neuroendocrine tumours","volume":"165","year":"2010","journal-title":"Regulatory Peptides"}],"container-title":["Endocrine Connections"],"original-title":[],"link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/7\/6\/EC-18-0059.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ec.bioscientifica.com\/downloadpdf\/journals\/ec\/7\/6\/EC-18-0059.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:42:46Z","timestamp":1784554966000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/ec\/article\/7\/6\/803-810\/330"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":66,"journal-issue":{"issue":"6"},"URL":"https:\/\/doi.org\/10.1530\/ec-18-0059","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}